RNS Number : 5934Z

OptiBiotix Health PLC

15 January 2024

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Launch of LeanBiome(R) in Muscletech(R)

OptiBiotix Health plc (AIM: OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare announces the forthcoming launch of LeanBiome(R) in Muscletech(R), one of the leading sports nutrition brands in the industry and backed by America's No. 1 selling sports supplement company (see About Us -- MuscleTech ). The product is currently being advertised on social media by the Company's partner ahead of online and instore launches with multiple retailers in Sweden, France, Poland, Germany, the Netherlands, Greece and the UK - see https://www.stack3d.com/2024/01/muscletech-nitro-tech-ripped-europe.html

Muscletech (R) is known as a leading brand in the science nutrition space recognised for its research with scientific experts to identify and utilise science backed ingredients in their products to bring unique benefits to athletes and fitness enthusiasts around the world. LeanBiome(R) will be incorporated in Muscletech Nitro Tech Ripped range, a premium protein powder designed to support athletes who want to lose fat and build lean muscle and will be launched in Europe and the United Kingdom across multiple e-commerce sites and distribution channels.

LeanBiome(R) is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix to support athletes seeking to increase lean muscle mass and to change their body composition. LeanBiome(R) contains a patented combination of fibres, prebiotics and minerals developed to increase the microbiome diversity of athletes on a high protein diet. A diverse microbiome is important in harvesting essential nutrients from the diet and has been linked to improved health and wellbeing and increased resilience to disease. Many researchers now believe that a diverse microbiome is an essential factor in achieving physical fitness, which was previously thought to be achievable solely through a healthy diet and regular exercise. This is supported by the growing scientific evidence of a link between the microbiome and athletic performance which suggest that optimizing an athletes gut microbiome could improve and athletes stamina, lower inflammation, and support physical fitness ( Frontiers | Editorial: Nutrition to support gut health and the microbiome in athletes (frontiersin.org)

Stephen OHara, C EO of O pti B i oti x Health plc c o mmented : "We are very pleased to announce the launch of LeanBiome (R) with such a well-known and internationally respected sports brand such as Muscletech (R) . LeanBiome(R) has been formulated to support anyone interested in improving their fitness for leisure or the elite athlete. It is supported by multiple published clinical studies which show it helps reduce body fat around the waist and hips, improving body leanness whilst enhancing the diversity of the gut microbiome to improve stamina and overall fitness.

"LeanBiome(R) is a unique product which is increasingly being recognised by major sports brands as a key differentiator from existing products and has the potential to have a major impact in the sports nutrition and health and fitness markets ."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc                                  www.optibiotix.com 
Neil Davidson, Chairman                        Contact via Walbrook below 
Stephen O'Hara, Chief Executive 
Cairn Financial Advisers LLP (NOMAD)                   Tel: 020 7213 0880 
Liam Murray / Jo Turner / Ludovico Lazzaretti 
Peterhouse Capital Limited (Broker)                    Tel: 020 7220 9797 
Duncan Vasey / Lucy Williams 
Walbrook PR Ltd                                        Mob: 07876 741 001 
Anna Dunphy 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

January 15, 2024 02:00 ET (07:00 GMT)

Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Optibiotix Health
Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Optibiotix Health